Your browser doesn't support javascript.
loading
Reduced Ejection Fraction in Elite Endurance Athletes: Clinical and Genetic Overlap With Dilated Cardiomyopathy.
Claessen, Guido; De Bosscher, Ruben; Janssens, Kristel; Young, Paul; Dausin, Christophe; Claeys, Mathias; Claus, Piet; Goetschalckx, Kaatje; Bogaert, Jan; Mitchell, Amy M; Flannery, Michael D; Elliott, Adrian D; Yu, Chenglong; Ghekiere, Olivier; Robyns, Tomas; Van De Heyning, Caroline M; Sanders, Prashanthan; Kalman, Jonathan M; Ohanian, Monique; Soka, Magdalena; Rath, Emma; Giannoulatou, Eleni; Johnson, Renee; Lacaze, Paul; Herbots, Lieven; Willems, Rik; Fatkin, Diane; Heidbuchel, Hein; La Gerche, André.
Afiliación
  • Claessen G; Faculty of Medicine and Life Sciences, Limburg Clinical Research Center (LCRC), Hasselt University, Biomedical Research Institute, Diepenbeek, Belgium (G.C., O.G., L.H.).
  • De Bosscher R; Hartcentrum Hasselt (G.C., L.H.), KU Leuven, Belgium.
  • Janssens K; Jessa Ziekenhuis, Belgium. Department of Cardiovascular Sciences (G.C., R.D.B., M.C., P.C., T.R., R.W., A.L.G.), KU Leuven, Belgium.
  • Young P; Jessa Ziekenhuis, Belgium. Department of Cardiovascular Sciences (G.C., R.D.B., M.C., P.C., T.R., R.W., A.L.G.), KU Leuven, Belgium.
  • Dausin C; Department of Cardiovascular Diseases (R.D.B., K.G., T.R., R.W.), University Hospitals Leuven, Belgium.
  • Claeys M; HEART (Heart Exercise and Research Trials) Lab, St Vincent's Institute of Medical Research, Fitzroy, Australia (K.J., A.M.M., A.L.G.).
  • Claus P; Exercise and Nutrition Research Program, The Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne Australia (K.J.).
  • Goetschalckx K; Victor Chang Cardiac Research Institute, Darlinghurst, Australia (P.Y., M.O., M.S., E.R., E.G., R.J., D.F., A.L.G.).
  • Bogaert J; Department of Movement Sciences (C.D.), KU Leuven, Belgium.
  • Mitchell AM; Jessa Ziekenhuis, Belgium. Department of Cardiovascular Sciences (G.C., R.D.B., M.C., P.C., T.R., R.W., A.L.G.), KU Leuven, Belgium.
  • Flannery MD; Jessa Ziekenhuis, Belgium. Department of Cardiovascular Sciences (G.C., R.D.B., M.C., P.C., T.R., R.W., A.L.G.), KU Leuven, Belgium.
  • Elliott AD; Department of Cardiovascular Diseases (R.D.B., K.G., T.R., R.W.), University Hospitals Leuven, Belgium.
  • Yu C; Department of Imaging and Pathology (J.B.), KU Leuven, Belgium.
  • Ghekiere O; Department of Radiology (J.B.), University Hospitals Leuven, Belgium.
  • Robyns T; HEART (Heart Exercise and Research Trials) Lab, St Vincent's Institute of Medical Research, Fitzroy, Australia (K.J., A.M.M., A.L.G.).
  • Van De Heyning CM; Department of Medicine, University of Melbourne, Parkville, Australia (M.D.F., J.M.K., A.L.G.).
  • Sanders P; Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Australia (A.D.E., P.S.).
  • Kalman JM; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia (C.Y., P.L.).
  • Ohanian M; Faculty of Medicine and Life Sciences, Limburg Clinical Research Center (LCRC), Hasselt University, Biomedical Research Institute, Diepenbeek, Belgium (G.C., O.G., L.H.).
  • Soka M; Department of Radiology (O.G.), KU Leuven, Belgium.
  • Rath E; Jessa Ziekenhuis, Belgium. Department of Cardiovascular Sciences (G.C., R.D.B., M.C., P.C., T.R., R.W., A.L.G.), KU Leuven, Belgium.
  • Giannoulatou E; Department of Cardiovascular Diseases (R.D.B., K.G., T.R., R.W.), University Hospitals Leuven, Belgium.
  • Johnson R; Department of Cardiovascular Sciences, University of Antwerp, Belgium (C.M.V.D.H., H.H.).
  • Lacaze P; Department of Cardiology, University Hospital Antwerp, Belgium (C.M.V.D.H., H.H.).
  • Herbots L; Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Australia (A.D.E., P.S.).
  • Willems R; Department of Medicine, University of Melbourne, Parkville, Australia (M.D.F., J.M.K., A.L.G.).
  • Fatkin D; Department of Cardiology, Royal Melbourne Hospital, Australia (J.M.K.).
  • Heidbuchel H; Victor Chang Cardiac Research Institute, Darlinghurst, Australia (P.Y., M.O., M.S., E.R., E.G., R.J., D.F., A.L.G.).
  • La Gerche A; Victor Chang Cardiac Research Institute, Darlinghurst, Australia (P.Y., M.O., M.S., E.R., E.G., R.J., D.F., A.L.G.).
Circulation ; 149(18): 1405-1415, 2024 Apr 30.
Article en En | MEDLINE | ID: mdl-38109351
ABSTRACT

BACKGROUND:

Exercise-induced cardiac remodeling can be profound, resulting in clinical overlap with dilated cardiomyopathy, yet the significance of reduced ejection fraction (EF) in athletes is unclear. The aim is to assess the prevalence, clinical consequences, and genetic predisposition of reduced EF in athletes.

METHODS:

Young endurance athletes were recruited from elite training programs and underwent comprehensive cardiac phenotyping and genetic testing. Those with reduced EF using cardiac magnetic resonance imaging (defined as left ventricular EF <50%, or right ventricular EF <45%, or both) were compared with athletes with normal EF. A validated polygenic risk score for indexed left ventricular end-systolic volume (LVESVi-PRS), previously associated with dilated cardiomyopathy, was assessed. Clinical events were recorded over a mean of 4.4 years.

RESULTS:

Of the 281 elite endurance athletes (22±8 years, 79.7% male) undergoing comprehensive assessment, 44 of 281 (15.7%) had reduced left ventricular EF (N=12; 4.3%), right ventricular EF (N=14; 5.0%), or both (N=18; 6.4%). Reduced EF was associated with a higher burden of ventricular premature beats (13.6% versus 3.8% with >100 ventricular premature beats/24 h; P=0.008) and lower left ventricular global longitudinal strain (-17%±2% versus -19%±2%; P<0.001). Athletes with reduced EF had a higher mean LVESVi-PRS (0.57±0.13 versus 0.51±0.14; P=0.009) with athletes in the top decile of LVESVi-PRS having an 11-fold increase in the likelihood of reduced EF compared with those in the bottom decile (P=0.034). Male sex and higher LVESVi-PRS were the only significant predictors of reduced EF in a multivariate analysis that included age and fitness. During follow-up, no athletes developed symptomatic heart failure or arrhythmias. Two athletes died, 1 from trauma and 1 from sudden cardiac death, the latter having a reduced right ventricular EF and a LVESVi-PRS >95%.

CONCLUSIONS:

Reduced EF occurs in approximately 1 in 6 elite endurance athletes and is related to genetic predisposition in addition to exercise training. Genetic and imaging markers may help identify endurance athletes in whom scrutiny about long-term clinical outcomes may be appropriate. REGISTRATION URL https//www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374976&isReview=true; Unique identifier ACTRN12618000716268.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Volumen Sistólico / Cardiomiopatía Dilatada / Atletas Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Circulation Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Volumen Sistólico / Cardiomiopatía Dilatada / Atletas Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Circulation Año: 2024 Tipo del documento: Article